KTTA Stock — Pasithea Therapeutics Corp.: Cash, EV, Pipeline

Share price

$0.52

Market cap

$17.5M

Cash

$45.7M

Enterprise value

-$28.2M

Balance sheet

Cash	$45.7M
Debt	$0.0M
Net cash	$45.7M
Enterprise value	-$28.2M
Basic shares	33.4M shares
Fully diluted shares	41.0M shares
Fully diluted market cap	$21.3M
Cash per share	$1.37

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading KTTA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	PAS-004 Tablets	Phase 1	NF1 Mutation; Neurofibroma Plexiform; Neurofibroma, Plexiform	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PAS-004

Phase 1 · Active Modality: small molecule (macrocyclic, oral)

Target MEK

Partnerships ALS Association ($1M Hoffman Clinical Trial Awards Program award, Nov 2025, for investigator-initiated trial of PAS-004 in ALS; terms being negotiated)

Indications

NF1 plexiform neurofibromas (adult) (Phase 1)
MAPK pathway-driven advanced solid tumors (Phase 1)
NF1 plexiform neurofibromas (pediatric) (Stage not disclosed)

Catalysts

— None
— None

Status note Next-generation oral once-daily macrocyclic MEK inhibitor for long-term treatment of chronic diseases including NF1. First-in-human Phase 1 Advanced Cancer Study ongoing. Phase 1/1b Adult NF1 trial initiated May 2025, first patient dosed late July 2025. Pediatric NF1-PN Phase 1 and registrational trials in adult and pediatric populations planned.

PAS-001

Discovery · Active

Target C4A

Indications

Schizophrenia (Discovery)

Status note Discovery-stage program for the treatment of schizophrenia.

PAS-003

Stage not disclosed · Terminated

Indications

Amyotrophic lateral sclerosis (ALS) (Stage not disclosed)

Status note Company determined to cease further development of the PAS-003 program for ALS during the year ended Dec 31, 2025, citing significant capital, resources and time required to develop the program.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PAS-004 Tablets
Lead indication	NF1 Mutation
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06961565	Phase 1	Recruiting	Sponsor	KTTA	—	NF1 Mutation; Neurofibroma Plexiform; Neurofibroma, Plexiform	—
NCT06299839	Phase 1	Recruiting	Sponsor	KTTA	—	RAS Mutation; NF1 Mutation; RAF Mutation	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Pasithea Therapeutics Corp. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

KTTA — Pasithea Therapeutics Corp.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials